MedTrace Logo

Platelet-Rich and Concentrated Platelet-Poor Plasma to Reduce Air Leak Post-Lobectomy: A Randomized Controlled Trial

NCT00665912 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 204

Last updated 2017-03-13

No results posted yet for this study

Summary

The purpose of this study is to determine whether the use of platelet-rich plasma (PRP) and concentrated platelet-poor plasma (PPPc) can reduce the duration of post-operative air leak after lobectomy for lung tumours.

Conditions

Interventions

PROCEDURE

Standard post-lobectomy wound care plus use of PRP and PPPc prepared by GPS and Plasmax respectively

GPS is used to create the platelet rich plasma (PRP). Plasmax is used to create the concentrated platelet-poor plasma (PPPc). Both PRP and PPPc will be used for wound care in the thoracic cavity post-lobectomy.

PROCEDURE

Standard post-lobectomy wound care

Standard post-lobectomy wound care

Sponsors & Collaborators

  • University of Western Ontario, Canada

    collaborator OTHER

  • Zimmer Biomet

    lead INDUSTRY

Principal Investigators

  • Richard Inculet, MD, FRCSC, FACS · Western University, Canada

  • Darrin Payne, MD · Western University, Canada

  • Dalilah Fortin, MD · Western University, Canada

  • Richard Malthaner, MD · Western University, Canada

  • Robert Humphrey, MD · Western University, Canada

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2010-05-31
Completion
2010-11-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00665912 on ClinicalTrials.gov